The FDA has approved the first oral interleukin (IL)-23-targeted therapy for plaque psoriasis, Johnson & Johnson announced. The approval of icotrokinra (Icotyde) stipulates use in adults and children ...

Adults with moderate to severe plaque psoriasis saw the greatest mean quality-of-life gains with biologic therapy whereas home phototherapy offered lower costs for patients and payers, according to a ...

Johnson & Johnson and Protagonist Therapeutics are countering the swarm of injectable biologics that have long dominated the lucrative psoriasis market with a new approval for a much-anticipate | The ...

By Sriparna Roy March 18 (Reuters) - The U.S. Food and Drug Administration has approved Johnson & Johnson's oral pill for psoriasis, the company said on Wednesday, paving the way for a more convenient ...

The company said the FDA approved Icotyde to treat moderate to severe plaque psoriasis in adults and pediatric patients 12 ...

Alumis said its drug, envudeucitinib, met all primary and secondary endpoints in two Phase 3 trials in patients with moderate-to-severe plaque psoriasis. About 65% of patients achieved near-complete ...

Add Yahoo as a preferred source to see more of our stories on Google. Whether you suffer from psoriasis yourself or have heard about it from a famous Kardashian who has been very transparent about her ...

The FDA approved icotrokinra for adults and adolescents aged 12 years and older with moderate to severe plaque psoriasis, Johnson & Johnson announced in a press release. Icotrokinra (Icotyde) is the ...

If you’ve just been diagnosed with psoriasis, you’re far from alone: 125 million people worldwide have this condition, with over 8 million in the U.S. alone. Psoriasis is a chronic autoimmune ...

FDA authorization covers moderate-to-severe plaque psoriasis in adults and patients aged ≥12 years, expanding systemic options for adolescents. Icotrokinra is characterized as a first-in-class ...

Psoriasis is an autoimmune condition that causes rough patches of skin. The new once-daily Icotyde pill, is an interleukin-23 (IL-23) receptor antagonist that has been found safe and also delivers ...

Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that it will present new ...